Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2020-03-15 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix and partners receive 500k CRC research grant 3 pages 193.2KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals and partners have received a $500,000 research grant from a government-funded organization to advance manufacturing of novel cancer drugs. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or operational report. The content is focused on a grant award and research collaboration, which is a corporate announcement related to capital or financing activities (funding/grant). The document length is about 8,000 characters, which is consistent with a detailed announcement but not a full financial report. There is no indication that this is an annual report, interim report, or any other formal regulatory filing. Therefore, the best fitting category is Capital/Financing Update (CAP).
2020-03-15 English
Business Update - COVID-19 2 pages 191.9KB
Regulatory Filings Classification · 95% confidence The document is a business update from Telix Pharmaceuticals Limited regarding the impact of the COVID-19 pandemic on its operations and clinical trials. It provides information on precautionary measures, risk management, and potential delays in business objectives. The document is not a financial report, earnings release, or regulatory filing. It is a corporate announcement aimed at informing shareholders and stakeholders about current business conditions and risks. The length is under 5,000 characters and it does not contain financial statements or detailed financial data. It is not an announcement of voting results, nor a management or board change notice. The content fits best as a general regulatory announcement or business update that does not fit into more specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-03-12 English
Prof. Frederik Giesel joins Scientific Advisory Board 2 pages 191.8KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Professor Frederik L. Giesel to the Scientific Advisory Board of Telix Pharmaceuticals Limited. It contains no financial data, no regulatory filings, no voting results, no capital changes, no earnings information, and no detailed report content. The document is an announcement related to management or board-level changes, specifically the addition of a scientific advisory board member, which falls under Board/Management Information (MANG). The document length is 3592 characters, which is relatively short and consistent with an announcement rather than a detailed report or presentation.
2020-03-08 English
Appendix 3Y - Change in Director Interests - M Nelson 3 pages 102.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the interest, and transaction details. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and contains detailed transaction data, not just an announcement or certification. Therefore, the correct classification is DIRS.
2020-03-03 English
Positive FDA feedback on NDA submission process 2 pages 183.3KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Telix Pharmaceuticals Limited regarding positive feedback from the FDA on their New Drug Application (NDA) submission process for a specific product (TLX591-CDx). It discusses regulatory feedback, timelines for submission, and corporate contact information. There are no financial statements, detailed financial data, or comprehensive report content. The document is relatively short (3942 characters) and serves as an update on regulatory progress rather than a full report or detailed financial disclosure. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. It is also not a voting result, capital update, or legal proceeding. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA feedback and submission plans, which does not fit other more specific categories.
2020-02-24 English
Appendix 4G - Key to Governance Disclosures 11 pages 187.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. The document includes detailed tables showing compliance with corporate governance recommendations for the financial year ended 31 December 2019. It is a governance-related disclosure document, not a full annual report or financial statement. It is not a brief announcement or a certification but a detailed governance disclosure. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2020-02-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.